One dose of COVID-19 vaccines effective against hospitalisations in over 80s
Press release issued: 3 March 2021
Interim results presented here show the effectiveness of one dose of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in preventing hospitalisation of people in their 80s with multiple comorbidities. The AvonCAP study results are reported for the first time today [3 March] by researchers from the University of Bristol, University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) and North Bristol NHS Trust (NBT).
AvonCAP, an ongoing surveillance project funded by Pfizer Inc., records detailed information on every adult patient admitted to Bristol’s two large NHS hospitals with symptoms, signs and/or X-ray evidence of acute disease in the lungs. The study identified 466 cases from 18 December 2020 (ten days after the UK’s COVID-19 vaccine programme began) to 26 February 2021 and who were eligible for vaccination due to being at least 80 years of age by the end of March 2021.
By taking the acute respiratory disease cases who had a positive test for SARS-CoV-2 on hospital admission and those whose test was negative and comparing the immunisation rates in the two groups, the effectiveness of one dose of the vaccines has been estimated.
In order to minimise potential biases that could arise due to the rapid changes in the epidemic and the vaccine rollout over this period, the analysis was structured so that comparisons were only made within individual weeks. A measure of social deprivation, whether patients were care home residents and sex – all factors which might influence the risks of getting COVID-19 and of getting immunised – were also considered.
One dose of the Pfizer-BioNTech vaccine, which began to be used on 8 December 2020, was shown to be 71.4 per cent effective (95 per cent confidence interval [CI] 46.5-90.6) from 14 days after one dose at preventing symptomatic illness severe enough to result in hospitalisation. The patients studied had a median age of 87 years.
One dose of the Oxford-AstraZeneca vaccine, which began to be used on 4 January 2021, was shown to be 80.4 per cent effective (95 per cent CI 36.4-94.5) from 14 days after one dose at preventing symptomatic illness severe enough to result in hospitalisation. The patients studied had a median age of 88 years.
When observations were reconciled to cover the same time period in early 2021, the observed effectiveness of one dose of the two vaccines were almost identical (Pfizer-BioNTech 79.3 per cent and Oxford-AstraZeneca 80.4 per cent).
These are similar to findings from other studies from Scotland and England made public in recent days. However, the approach taken was different. Instead of linking large databases of test results, immunisation records and diagnostic codes for entire populations, this study involved comprehensive and detailed examination of all medical admissions in two admitting hospitals in a single city. This means that the dates of onset of symptoms could be accurately recorded and included in the analysis and compensation made for possible biases due to rapid changes in the vaccine rollout and the transmission of SARS- CoV-2 that occurred during the last three months.
The study also provides very detailed information on the patients who were hospitalised and in whom the vaccines are taking effect. This was a group of very elderly, frail people with many other illnesses and vulnerabilities and it is particularly remarkable that vaccination was able to protect such high-risk people so effectively.
By providing corroborating evidence using a different methodology, the research team provide reassurance that the conclusions now being drawn about the short-term effectiveness of one dose of these two vaccines is valid.
The public health implications of these findings are significant not only for the UK but also for other countries currently developing immunisation strategies to protect their vulnerable elderly populations.
Adam Finn, Professor of Paediatrics and Chief Investigator of the study at the University of Bristol, said: “We are very pleased to share these early results that show the UK COVID-19 vaccine programme is working better than we could have hoped. We are also delighted our findings could reduce the burden of serious illness in our elderly population and relieve the pressure on the NHS. The AvonCAP study will continue to provide further and more detailed information as time goes on.”
'Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in prevention of hospitalisations in elderly and frail adults: a single centre test negative case-control study' by Hyams, Catherine and Marlow, Robin, Danon, Leon and Finn, Adam et al in The Lancet
Please note this is a preprint, so it is a preliminary piece of research that has not yet been through peer review and has not been published in a scientific journal – so this is early data
Peer reviewed paper [published 23 June 2021]
'Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study' by Hyams, Catherine and Marlow, Robin, Danon, Leon and Finn, Adam et al in The Lancet Infectious Diseases
About the AvonCAP study
The AvonCAP (community-acquired pneumonia) study from Bristol is a prospective test negative case control study of adult respiratory infection and vaccine-preventable pneumococcal disease in the context of COVID-19 admitted to two large NHS hospitals.
About coronavirus (SARS-CoV-2)
The surface of the coronavirus particle has proteins sticking out of it known as Spike proteins which are embedded in a membrane. They have the appearance of tiny little crowns, giving the virus its name (corona). Inside the membrane is the viral genome wrapped up in other proteins. The genome contains all the genetic instruction to mass produce the virus. Once the virus attaches to the outside of a human cell, its membrane fuses with the human cell membrane and its genetic information passes into the human cell. Next, the virus instructs the cell to start replicating its genome and produce its proteins. These are then assembled into many new copies of the virus which, upon release, can infect many more cells. The viral proteins play diverse further roles in coronavirus pathology.
Support our COVID-19 research
Bristol’s researchers are part of a global network of scientists responding urgently to the challenge of the coronavirus pandemic.
Bristol UNCOVER Group
In response to the COVID-19 crisis, researchers at the University of Bristol formed the Bristol COVID Emergency Research Group (UNCOVER) to pool resources, capacities and research efforts to combat this infection.
Bristol UNCOVER includes clinicians, immunologists, virologists, synthetic biologists, aerosol scientists, epidemiologists and mathematical modellers and has links to behavioural and social scientists, ethicists and lawyers.
Follow Bristol UNCOVER on Twitter at: twitter.com/BristolUncover
For more information about the University of Bristol’s coronavirus (COVID-19) research priorities visit: http://www.bristol.ac.uk/research/impact/coronavirus/research-priorities/
Bristol UNCOVER is supported by the Elizabeth Blackwell Institute
Find out more about the Institute’s COVID-19 research looking into five key areas: virus natural history, therapeutics and diagnostics research; epidemiology; clinical management; vaccines; and ethics and social science.